[Using phospholipids modified according to the method of liposome technology in the treatment of patients with chronic renal insufficiency].
The article deals with treatment of chronic renal insufficiency, which is an issue of the day. 35 patients with chronic renal insufficiency (CRI) at I-II stages irrespective of primary nosological diagnosis have been investigated. It was the first time when LIPIN was prescribed at a total dose of 20 mg/kg to improve the methods of conservative therapy. The material presents dynamics of laboratory indices of renal function over treatment with LIPIN. It was established, that LIPIN statistically reliably decreases creatinine and urea level in patient's blood, absolutely brings down transmidase blood serum activity, reduce clinical presentations of uremic gastroenteropathy as well as improves general state of health.
Stepanova
N M
NM
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008081:Liposomes; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals; D010743:Phospholipids / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index; D000637:Transaminases / Q000097:blood; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D008081:Liposomes; D009930:Organic Chemicals; D010743:Phospholipids; C088310:lipine; D003404:Creatinine; D000637:Transaminases